No­var­tis' Tafin­lar/Mekin­ist com­bo scores new in­di­ca­tion in pe­di­atric brain can­cer

No­var­tis’ Tafin­lar (dabrafenib) and Mekin­ist (tram­e­tinib) com­bo has been ap­proved for an­oth­er in­di­ca­tion by the FDA — this time for treat­ment of low-grade glioma with a BRAF V600E mu­ta­tion in kids aged 1 year and up.

This marks the sixth ap­proval for the com­bi­na­tion. It’s al­ready ap­proved for use in mul­ti­ple BRAF V600E sol­id tu­mors, in­clud­ing melanoma, thy­roid can­cer and lung can­cer.

Liq­uid for­mu­la­tions for both drugs were al­so ap­proved by the FDA, which No­var­tis said is the first time a BRAF/MEK in­hibitor has been de­vel­oped in a for­mu­la­tion suit­able for pa­tients as young as one.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER